Thursday, December 3, 2020
Home Latest Pharma-News SurVaxM: A novel anti-cancer immunotherapy for the treatment of glioblastoma brain cancers

SurVaxM: A novel anti-cancer immunotherapy for the treatment of glioblastoma brain cancers

Nov 15, 2019: Shanghai Fosun Pharmaceutical and MimiVax LLC have entered into a China-exclusive licensing agreement for the clinical development and commercialization of SurVaxM.

SurVaxM is first-in-class, patented peptide immunogen targeting Survivin Antigen on tumor cells, a novel anti-cancer immunotherapy in the treatment of newly diagnosed glioblastoma brain cancers.

- Advertisement -

Glioblastoma is an adult-common malignant neuroepithelial neoplasm in the central nervous system, the tumor has a fast growth rate, with 70-80% of patients surviving a disease course of only 3 to 6 months ( most devastating type in the WHO  classification  of central nervous system tumors).  

Presently, patient’s survival time is in the range of 14.5 to 16.6 months when treated with surgery, radiotherapy, chemotherapy and other supportive therapy.SurVaxM stimulates the production T-cell and B cell immunity simultaneously with unique cellular and antibody-mediated anti-tumor responses.

https://www.fosunpharma.com/en/news/news-details-3786.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

15 + 15 =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...